v3.26.1
Collaborative Agreements (Details) - USD ($)
$ / shares in Units, shares in Thousands
3 Months Ended 12 Months Ended
Jun. 18, 2024
May 23, 2024
May 14, 2024
May 08, 2024
Apr. 16, 2024
Mar. 25, 2024
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2024
Jul. 16, 2025
Collaborative Agreements [Line Items]                    
Licensing fee           $ 33,500,000        
FEYE stock (in Dollars per share)                   $ 1.65
Milestone regulatory payment amount $ 3,500,000         $ 3,500,000        
Percentage of royalties of net sales           5.00%        
Cash receipt                
Cash and recognized revenue                 $ 200,000  
Number of shares received (in Shares)   1,250 1,250       1,250      
Cash receipt                
Collaborative agreement with ForSeeCon Eye Corporation [Member]                    
Collaborative Agreements [Line Items]                    
Upfront payment           $ 30,000,000        
Number of shares paid of licensing agreement (in Shares)           5,000        
FEYE stock (in Dollars per share)           $ 6        
Shares received (in Shares)               5,000    
OncoX BioPharma, Inc., [Member]                    
Collaborative Agreements [Line Items]                    
Consideration paid   $ 6,250,000 $ 6,250,000 $ 6,250,000 $ 6,250,000          
Shares issued (in Shares)   1,250 1,250 1,250 1,250          
Price per share (in Dollars per share)   $ 5 $ 5 $ 5 $ 5          
Additional milestone payment in cash   $ 625,000 $ 625,000 $ 625,000 $ 625,000          
Royalty percentage   5.00% 5.00% 5.00% 5.00%          
Number of shares received (in Shares)             1,250      
Percentage of develop and commercialize   50.00% 50.00% 50.00%            
Licensing fees   $ 100,000 $ 100,000 $ 100,000            
ForSeeCon Eye Corporation [Member]                    
Collaborative Agreements [Line Items]                    
Licensing agreement $ 100,000